Scottish Medicines Consortium approval of VPRIV
Shire Human Genetics applied to the Scottish Medicines Consortium (SMC) for approval of VPRIV. The SMC approached The Gauchers Association to provide information to be considered alongside Shire's submission. We are delighted to inform you that on Monday (8th October) the SMC announced their approval on the use of VPRIV in the treatment of Gaucher disease in Scotland. This will enable new patients who were prescribed the therapy to access funding.
The link to the announcement is: